Clinical trials: Bone Marrow Suppression
Graft Versus Host Disease
Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant
This trial will see if extended abatacept administration (combined with a standard regimen of tacrolimus and mycophenolate mofetil) will prevent acute and chronic graft-versus-host disease (GVHD) in children and adolescents…
- Trial name
- ASCENT (NCT03924401)
- Testing
- Abatacept
- Where
- 9 sites in United States
- Volunteers
- 30 people
- Sponsor
- Emory University
Myelosuppression
Trilaciclib Prevents Myelosuppression With Chemoradiotherapy
To evaluate the protective effect of Trilaciclib on myelosuppression in patients with limited-stage small cell lung cancer associated with concurrent chemoradiotherapy and discuss the effect of gut microbiota changes on…
- Trial name
- NCT06490081
- Testing
- Trilaciclib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Ovarian Neoplasms, Ovarian Cancer
OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study
Ovarian cancer (OC) is one of the most lethal cancers in the world due to late-stage disease at diagnosis. Standard therapy consists of debulking surgery and chemotherapy.
- Conditions
- Ovarian Neoplasms, Ovarian Cancer, Ovarian Carcinoma, Immune Suppression
- Trial name
- RENAISSANCE (NCT06611072)
- Testing
- Bone marrow aspiration, Vena puncture, Peritoneal fluid
- Where
- Netherlands
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Gynaecologisch Oncologisch Centrum Zuid
Breast Cancer
Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients
The primary purpose of this study is to measure the association between baseline expression of the senescence effector protein p16INK4a and myelosuppression due to chemotherapy in patients with breast cancer.
- Trial name
- NCT01305954
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Bone Marrow Suppression, Brain and Central Nervous System Tumors
Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
- Trial name
- NCT00005796
- Testing
- filgrastim, gene therapy, lomustine
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Indiana University
Non-small Cell Lung Cancer
Study on the Association of GSTP1 and Other Gene Polymorphisms With Platinum-induced Myelosuppression
This study intends to design a retrospective and prospective, cohort study to explore the association between genetic polymorphism of GSTP1 A313G rs1695 or others and adverse effects of platinum drugs, aiming to explore the risk…
- Trial name
- NCT06140082
- Testing
- GSTP1 A313G （AA）
- Volunteers
- 477 people
- Sponsor
- LI YAN
Breast Cancer
A Study to Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)
The purpose of this study is to explore risk factors for grade 4 neutropenia in users of the study medicine Palbociclib for the potential treatment of Palbociclib.
- Trial name
- NCT05709158
- Where
- United States
- Volunteers
- 4,184 people
- Sponsor
- Pfizer
Urothelial Carcinoma, Bladder Cancer
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy…
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Myelosuppression Adult, Chemotherapy-induced Neutropenia
- Trial name
- PRESERVE3 (NCT04887831)
- Testing
- Trilaciclib, Gemcitabine, Cisplatin
- Where
- 34 sites in United States, France and 3 more
- Volunteers
- 92 people
- Sponsor
- G1 Therapeutics, Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC)
Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This prospective, single-arm, exploratory, phase II study was designed to evaluate the efficacy and safety of Trilaciclib in reducing chemotherapy-induced neutropenia in patients with recurrent or metastatic head and neck…
- Trial name
- NCT06714266
- Testing
- Trilaciclib
- Volunteers
- 30 people
- Sponsor
- Shandong Cancer Hospital and Institute
Endothelial Dysfunction, Metabolic Syndrome
Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.
This study is to compare the safety and efficacy of UCMSCs and BMMSCs administered intravenously in patients to evaluate cytokine suppression in patients with chronic inflammation.
- Conditions
- Endothelial Dysfunction, Metabolic Syndrome, Chronic Inflammation
- Trial name
- CERES (NCT03059355)
- Testing
- UCMSCs, BMMSCs
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Joshua M Hare
Breast Cancer, Bone Marrow Suppression
A Randomized, Self-controlled Post-marketing Clinical Study on the Comparison of Shengbai Oral Liquid and Leucogen Tablets in the Treatment of Moderate Neutropenia Caused by Anti-tumor Drugs in Breast Cancer Patients
The subjects were randomly assigned to Group A or Group B in a 1:1 ratio, stratified by early/late stage. Group A: In the first cycle, they took Shengbai Oral Liquid (40 ml, three times a day), and in the second cycle, they took…
- Trial name
- NCT07578064
- Testing
- Group A, Group B
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hongxia Wang
Chemotherapy-Induced Myelosuppression
Careseng 1370 for Chemotherapy-Induced Myelosuppression
This is a Phase I/IIa dose-finding (Phase I) followed by randomized, double-blind, placebo-controlled, parallel, add-on to cisplatin + docetaxel (Phase IIa) study to evaluate the safety, tolerability, and efficacy profiles of…
- Trial name
- NCT03692780
- Testing
- Careseng 1370
- Sponsor
- Careseng Biotech Co., Ltd.
Cytomegalovirus Retinitis, HIV Infections
A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Cannot Use Ganciclovir
To study the safety and effectiveness of foscarnet in the treatment of AIDS patients who have active infection with cytomegalovirus (CMV) that is causing inflammation of the retina (retinitis).
- Trial name
- NCT00000697
- Testing
- Foscarnet sodium
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Myelosuppression Adult, Chemotherapeutic Toxicity
Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer
The purpose of this expanded access protocol is to provide access to trilaciclib for chemotherapy-induced myelosuppression in patients receiving chemotherapy as a treatment for small cell lung cancer (SCLC).
- Conditions
- Myelosuppression Adult, Chemotherapeutic Toxicity, Small Cell Lung Cancer
- Trial name
- NCT04504513
- Testing
- Trilaciclib
- Sponsor
- G1 Therapeutics, Inc.
Ewing Sarcoma, Myelosuppression
A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib
This study is a prospective, open label, randomized controlled clinical trial aimed at patients with Ewing's sarcoma who have not received systematic anti-tumor treatment in the past.
- Trial name
- NCT06699472
- Testing
- Chemotherapy, Trilaciclib Injection [Cosela]
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Fudan University
Gynecologic Cancer, Myelosuppression Adult
G-CSF for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients
This study aims to analyze the effects of long-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in gynecologic cancer patients.
- Conditions
- Gynecologic Cancer, Myelosuppression Adult, Febrile Neutropenia, Chemotherapy-induced Neutropenia
- Trial name
- NCT03793205
- Testing
- Long-acting G-CSF, Short-acting G-CSF
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Lei Li
ESCC
Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma
Clinical data of patients with synchronous radiotherapy for esophageal cancer in the Department of Radiology of Jiangsu Provincial People's Hospital were collected.
- Trial name
- COSELA (NCT06698692)
- Testing
- Trilaciclib Injection [Cosela]
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Triple Negative Breast Cancer
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
This was a Phase 2, multicenter, open-label, single-arm study evaluating the safety and efficacy of trilaciclib administered prior to sacituzumab govitecan-hziy in participants with unresectable, locally advanced or metastatic…
- Trial name
- NCT05113966
- Testing
- Trilaciclib, Sacituzumab Govitecan-hziy
- Where
- 22 sites in United States
- Volunteers
- 30 people
- Sponsor
- G1 Therapeutics, Inc.
Nasopharyngeal Carcinoma, Leucogen
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
Toxic and side effects during and after chemoradiotherapy for nasopharyngeal carcinoma seriously affect patients' treatment compliance and long-term quality of life.
- Conditions
- Nasopharyngeal Carcinoma, Leucogen, Chemotherapy, Myelosuppression
- Trial name
- NCT05780294
- Testing
- 5-fu, Lobaplatin, leucogen
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Sun Yat-sen University
Hematologic Neoplasms, Neutropenia
Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies
The purpose of the study is to explore the safety and efficacy of umbilical cord derived mesenchymal stem cells in treatment-induced myelosuppression in patients with hematologic malignancies.
- Conditions
- Hematologic Neoplasms, Neutropenia, Anemia, Thrombocytopenia
- Trial name
- NCT05672420
- Testing
- umbilical cord derived mesenchymal stem cells
- Where
- 3 sites in China
- Volunteers
- 181 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology